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Ubc9 was identified as a cellular protein that interacts with the Gag protein of Mason-Pfizer monkey virus.
We show here that Ubc9 also interacts with the human immunodeficiency virus type 1 (HIV-1) Gag protein and
that their interaction is important for virus replication. Gag was found to colocalize with Ubc9 predominantly
at perinuclear puncta. While cells in which Ubc9 expression was suppressed with RNA interference produced
normal numbers of virions, these particles were 8- to 10-fold less infectious than those produced in the
presence of Ubc9. The nature of this defect was assayed for dependence on Ubc9 during viral assembly,
trafficking, and Env incorporation. The Gag-mediated assembly of virus particles and protease-mediated
processing of Gag and Gag-Pol were unchanged in the absence of Ubc9. However, the stability of the cell-
associated Env glycoprotein was decreased and Env incorporation into released virions was altered. Interest-
ingly, overexpression of the Ubc9 trans-dominant-negative mutant C93A, which is a defective E2-SUMO-1
conjugase, suggests that this activity may not be required for interaction with Gag, virion assembly, or
infectivity. This finding demonstrates that Ubc9 plays an important role in the production of infectious HIV-1
virions.
Production of infectious human immunodeficiency virus
type 1 (HIV-1) particles is a coordinated series of poorly de-
fined events in which the virus takes advantage of cellular
components to target its structural proteins and genomic RNAs
to common sites on cellular membranes. This colocalization
drives the assembly of immature capsids, packaging of the
diploid viral genomic RNA, incorporation of viral glycopro-
teins and virion-associated proteins, and viral budding/release.
The major structural component of the immature HIV-1 core
is the Gag polyprotein. Gag is synthesized on cytoplasmic ri-
bosomes as a 55-kDa polyprotein, Pr55Gag, and is co- or post-
translationally myristylated. Expression of Gag alone is suffi-
cient for assembly and release of noninfectious virus-like
particles. However, infectivity of HIV-1 can only be attained by
inclusion of the receptor-binding Env glycoproteins (gp120 and
gp41) and the pol-encoded enzymes (protease, reverse trans-
criptase, and integrase). Protease is essential for the cleavage
of the Gag polyprotein into the structural proteins NH2-MA
(p17; the membrane-associated matrix protein), CA (p24; the
major capsid protein), SP1 (spacer peptide 1; also known as
p2), p17 (NC; the nucleocapsid protein), SP2 (spacer peptide
2; also known as p1), and p6-COOH (17, 73), to form the
mature, infectious virion. The cleavage of the precursor
polyprotein has been the target of the highly effective protease
inhibitor class of antiretrovirals.
Gag-mediated packaging of viral enzymes, structural pro-
teins (e.g., Gag-Pol polyprotein, mature Env glycoproteins,
Vpu, Vpr, and Vif), the vRNAs, and cellular components (e.g.,
cyclophilin A [16] and lysyl-tRNA) is necessary for the pro-
duction of infectious particles (17, 18, 73). Since these mole-
cules are synthesized in different cellular compartments, it is
imperative that cellular pathways traffic these components to
common assembly sites on infected cell membranes. Cell frac-
tionation, immunohistochemistry, and electron and fluores-
cence microscopy studies have shown that Gag assembles and
buds almost exclusively from the plasma membrane in primary
CD4 T cells and in most cell lines, such as HeLa, 293, and
COS-1 cells (25, 27, 51, 70). However, a significant but minor
portion of Pr55 in T cells can also be found associated with late
endosomes (LE) (20). These observations led to the postula-
tion that most Pr55Gag buds primarily from the plasma mem-
brane, but a portion of the polyprotein may fail to bud and may
cycle off the plasma membrane into the LE (23). Alternatively,
it has been suggested that Gag is initially targeted to the LE/
multivesicular body compartments and is subsequently trans-
ported to the plasma membrane (20, 48, 55, 56, 65). Consistent
with the latter hypothesis, further studies have shown that Gag
colocalizes with LE/multivesicular body marker proteins in infect-
ed/transfected cells and is packaged into released virions (35, 54).
However, follow-up studies have shown that the membranes of
these intracellular structures are contiguous with the plasma
membrane (12, 31, 72), and HIV-1 may utilize these tetraspanin-
enriched microdomains as assembly sites (12, 29). The current
model is that HIV-1 assembles and buds from specialized regions
of the plasma membrane in most, if not all, cell types.
The intracellular trafficking pathways of the viral structural
proteins must converge at common sites to allow the requisite
assembly interactions to occur. However, the intracellular lo-
cations of these interactions and the temporal or spatial reg-
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ulation of these events are not well defined. Gag and Gag-Pol
proteins are transported through the cytoplasm to cellular
membranes by poorly understood processes that likely involve
components of the cellular cytoskeletal system. The viral gly-
coproteins are synthesized on the rough endoplasmic reticu-
lum (ER) and are cotranslationally translocated into the ER
lumen as gp160 precursor proteins. The gp160 molecules are
heavily N- and O-linked glycosylated concomitant with trimer-
ization prior to being transported to the Golgi apparatus for
oligosaccharide maturation. During transport from the cis-me-
dial Golgi to the cell surface, gp160 is likely cleaved by furin in
the medial trans-Golgi (22, 46), yielding the mature surface
(gp120) and transmembrane (gp41) glycoproteins. However,
other proteases may also be involved (28, 49, 75).
It is hypothesized that Env trimers interact with Gag at
budding sites, yet biochemical and genetic evidence suggests
that the initial Gag-Env interactions, whether direct or indi-
rect, occur prior to their arrival at the final assembly sites (41,
42, 61, 64). In fact, Tip47, a tail-interacting protein involved in
retrograde transport of cellular factors from endosomes to the
trans-Golgi network (TGN), was found to be required for Env
packaging. This model suggests that during retrograde trans-
port to the TGN, Env comes into contact with Gag on endo-
somes, with Tip47 directly facilitating Gag-Env interaction.
This complex is then targeted to the final assembly site on the
plasma membrane (43).
Coordinated trafficking of Gag, Gag-Pol, and Env requires
interactions with cellular proteins. A number of host factors,
such as AP-1 (7), AP-2 (5), AP-3 (15), Rab9 (47), POSH (2),
PI(4,5)P2 (50), Tip47 (43), SOCS1 (58), Arf proteins (30), and
KIF4 (44), have been found to interact directly with HIV-1
structural proteins, promoting proper intracellular trafficking
and driving virion assembly. Ubc9, an E2 SUMO-conjugating
enzyme (63), was found to interact with several different ret-
roviral proteins, but its function during virus replication is
unclear. Ubc9 was shown to interact with the full-length Gag
protein of Mason-Pfizer monkey virus (M-PMV) near the nu-
clear membrane, suggestive of a possible function for Ubc9
during virus assembly (71). In contrast, Ubc9 was subsequently
shown to interact with and SUMOylate the CA protein of
Moloney murine leukemia virus (MLV) (76). Unlike the ob-
servations made with M-PMV, an interaction between the full-
length MLV Gag protein and Ubc9 was not observed in the
yeast two-hybrid assay. Biochemical and genetic analyses sug-
gested that the MLV CA-Ubc9 interaction is required during
the early stages of replication, post-reverse transcription.
Finally, Ubc9 was shown to interact with the HIV-1 p6gag
protein in yeast and to SUMOylate a p6-green fluorescent
protein (GFP) fusion protein in mammalian cells. Overexpres-
sion of SUMO-1 resulted in the packaging of free SUMO-1
into HIV-1 virions and was shown to cause a fivefold decrease
in the infectivity of these virions compared to virions pro-
duced in control cells. It was found that the defect in infectivity
of wild-type (wt) HIV-1 virions produced in the presence of
overexpressed SUMO-1 occurred during a postentry step (21),
which suggests that SUMOylation of p6 negatively regulates
HIV-1 infectivity during an early infectious event. Interest-
ingly, mutation of the SUMOylation site, in the context of an
infectious provirus, had no apparent effect on virus replication
in normal cells. However, unlike wt HIV-1, the SUMOylation
mutant did not exhibit a defect in virion infectivity when
SUMO-1 was overexpressed in producer cells. Thus, the role of
SUMOylation in p6 function is still not clear.
Recently, it was reported that GagGFP fusion protein colo-
calizes with myc-Ubc9 at Gag perinuclear clusters (GPCs) in
the absence of KIF4 (44), a kinesin family motor protein.
Blocking KIF4 function resulted in Gag accumulation at
GPCs, inhibiting Gag trafficking, stability, and subsequent
release. However, neither an interaction between Ubc9 and
full-length Pr55 nor SUMOylation of Pr55 by Ubc9 during
assembly was examined in the previous reports. In this study,
we further investigated the role of Ubc9 during HIV-1 repli-
cation. We demonstrated that (i) Ubc9 interacts with Pr55; (ii)
Ubc9 and C93A Ubc9, a trans-dominant negative mutant (68),
colocalize with Gag at perinuclear sites; (iii) Ubc9 is crucial
during the late stages of replication to produce infectious par-
ticles; and (iv) the E2 SUMO conjugation activity of Ubc9 does
not appear to be a prerequisite for its effect during the late
stages of the HIV-1 life cycle.
MATERIALS AND METHODS
Cell lines and bacterial strains. TZM-bl indicator cells were obtained from the
NIH AIDS Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH: TZM-bl from John C. Kappes, Xiaoyun Wu, and Tranzyme Inc.
The HeLa and 293T cells were obtained from the American Type Culture
Collection. Escherichia coli BL21 (DE3) cells were used for expression of gluta-
thione S-transferase (GST) and GST-Ubc9 (71).
Plasmids. The infectious HIV-1 proviral clone pNL4-3 and the noninfectious
clone pNL4-3-E-EGFP were obtained from the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH: pNL4-3 from Malcolm
Martin (1) and pNL4-3-E-EGFP (catalog no. 11100) from Haili Zhang, Yan
Zhou, and Robert Siliciano (78). The pLTR EnvNL4-3 construct encoding HIV-1
envelope was created by introducing an EcoRI site into pNL4-3 at position 823.
The 4,920-bp EcoRI (nucleotides 823 and 5743) fragment was removed, and
the remaining vector was religated. The plasmids pCMVgagpol-RRE-R and
pCMVrev, encoding HIV-1 Gag and Rev, respectively, were a kind gift from
David Rekosh (University of Virginia, Charlottesville) (37, 67). The in vitro Gag
expression plasmids pTM/55BAM, pGPG1-39G1, pGPG1-15G1, pGPG1-41G1,
pGPG1-17G1, and pGPG1-24G1 were a kind gift from Paul Spearman (Emory
University, Atlanta, GA) (66). The plasmid pHyg-VSV-G, encoding vesicular
stomatitis virus G protein, was a kind gift from Asit Pattnaik (University of
Nebraska—Lincoln). Plasmids pET41c (Novagen), pET Ubc9, pCMV-Tag3A,
and pCMV Myc-Ubc9 have been previously described (71). Myc-C93A was
created by PCR-based site directed mutagenesis of Myc-Ubc9 by mutating nu-
cleotides 276 and 277 to cytosine and guanine, respectively, in the Ubc9 open
reading frame. The plasmid pEGFP-SUMO-1, encoding an enhanced-GFP
(EGFP)–SUMO-1 fusion protein, was a kind gift from Yongsok Kim (33).
RNA interference (RNAi) and DNA transfections. Synthetic double-stranded
small interfering RNAs (siRNAs) with 3 dTdT overhangs, corresponding to
nucleotides 86 to 104 of the Ubc9 open reading frame, were purchased from
Dharmacon and are similar to those previously described (39). Fluorescent,
nonsilencing 21-bp double-stranded RNA (Qiagen) was used as a control RNA
(Ctr. RNA). 293T cells were transfected twice with RNAs, at 0 and 24 h, using
Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s pro-
tocol. After an additional 24 h, the cells were transfected with either plasmid
pNL4-3, pLTR EnvNL4-3, pNL4-3-Env-EGFP, or pNL4-3-E-EGFP with
pHyg-VSV-G. Plasmids pCMVgagpol-RRE-R and pCMVrev were cotrans-
fected into HeLa cells using Fugene 6 (Roche) according to the manufacturer’s
suggestions.
GST pull-down assays. pTM/55BAM, pGPG1-39G1, pGPG1-15G1, pGPG1-
41G1, pGPG1-17G1, and pGPG1-24G1 were used to express [35S]methionine-
cysteine-radiolabeled wt Gag and Gag deletion mutants using the TNT Coupled
Reticulocyte Lysate System (Promega). GST-Ubc9 (pET Ubc9) and GST
(pET41c) were expressed in and purified from E. coli as previously described.
Radiolabeled Gag or Gag deletion mutants were incubated with equimolar
concentrations of GST or GST-Ubc9 and immobilized on glutathione beads, and
pull-down assays were carried out as previously described (71).
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Viral-infectivity assays. Virus released into the culture media from transfected
cells was quantified by determining the amount of released p24 by immunoblot-
ting. TZM-bl indicator cells were infected with equivalent amounts of viruses
(normalized to the p24 content). The number of infected cells in this infectivity
assay was determined by staining for -galactosidase activity at 36 h postinfection
as previously described (34).
Antibodies. Anti-Ubc9 (H-81) rabbit polyclonal antibodies (PAb), anti-actin
goat PAb, anti-cyclophilin A PAb, HIV-1 anti-gp41 (10E9) monoclonal antibod-
ies (MAb), and horseradish peroxidase (HRP)-conjugated chicken anti-goat
PAb were purchased from Santa Cruz Biotechnology, Inc. The following rabbit,
goat, and mouse anti-HIV-1 antibodies were obtained from the NIH AIDS
Research and Reference Reagent Program: anti-p24 MAb 24-2, gp41 MAb 2F5,
HIV-1sf2 p24 PAb, HIV-1 gp160/120 goat PAb H3T, HIV-1HXB2 Vif PAb,
HIV-1NL4-3 Vpu PAb, and Vpr PAb. Anti-SUMO-1 no. 12783 rabbit PAb, a kind
gift from Van Wilson (Texas A&M University System Health Science Center,
College Station), were previously described (57). HRP-conjugated goat anti-
rabbit and HRP-conjugated sheep anti-human antibodies were purchased from
Amersham Pharmacia Biotech. Cy5-conjugated donkey anti-mouse and Cy2-
conjugated donkey anti-rabbit sera were purchased from Jackson Immunore-
search Laboratories. Pooled AIDS patient sera and pooled normal human sera
were obtained from a patient cohort.
Immunoblotting analysis. Media from transfected cells were harvested, and
virions were purified from the media by pelleting them through a 20% sucrose
cushion (6). The pelleted virions and cells were solubilized directly in 2 protein
sample buffer (PSB), separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), and analyzed by immunoblotting. For immuno-
blot detection of SUMOylated proteins, transfected cells were lysed as previously
described (4) with SUMO lysis buffer containing 20 mM iodoacetamide and
N-ethylmaleimide. The lysates were separated by SDS-PAGE, transferred to a
polyvinylidene difluoride membrane (GE Healthcare), and analyzed by immu-
noblotting.
vRNA extraction and real-time PCR. Viral RNA (vRNA) was extracted from
equal numbers of virions (normalized by p24 content) and reverse transcribed
(6). Viral cDNA was quantified by real-time PCR (iCyclerIQ; Bio-Rad) using
previously described primers (10).
Cell viability assay. The viability of Ubc9 siRNA-transfected cells and control
cells was assayed using BD ApoAlert Annexin V and an Apo 2.7-PE kit (BD
Biosciences) according to the manufacturer’s protocol. Annexin-EGFP V stain-
ing and propidium iodide uptake were measured using a BD FACSCalibur (BD
Biosciences).
Confocal microscopy. Transfected 293T cells were cultured on sterile cover-
slips treated with poly-L-lysine in 35-mm culture dishes. The cells were fixed at
room temperature in 4% paraformaldehyde in phosphate-buffered saline (PBS)
for 20 min and permeabilized with 0.2% Triton X-100 in PBS for 5 min. The fixed
cells were processed and stained as previously described (6). The coverslips were
mounted on slides and analyzed by confocal microscopy (Olympus FV500 with
an upright BX Olympus fluorescence microscope). Proteins in transfected cells
were detected using the following antibodies: Pr55, anti-p24 MAb, Env, anti-
gp41 MAb 10E9, Ubc9, and anti-Ubc9 PAbs. Fluorescent Cy5-conjugated don-
key anti-mouse and Cy2-conjugated donkey anti-rabbit antibodies were used as
secondary antibodies. Anti-Ubc9 antibodies were not able to detect endogenous
Ubc9 in this assay. Consequently, Cy2 background antibody staining and any
potential low-level endogenous Ubc9 staining signals were reduced to undetect-
able levels; thus, the fluorescent signals detected were due to exogenous protein
expression only. Z sections (0.3 m) were analyzed using Flowview imaging
software (Olympus).
Metabolic labeling and immunoprecipitation. Transfected 293T cells were
pulse-labeled for 45 min with 300 Ci [35S]methionine/cysteine (1,000 Ci/
mmol; NEN). The labeling media were removed, and the cells were chased for
2 and 4 h in normal growth media. The cell culture supernatants were then
collected, clarified by centrifugation (13,800  g for 1 min), and adjusted to 1
lysis buffer (60). The cells were lysed with 1 lysis buffer containing protease
inhibitors (Roche) and centrifuged to remove cellular debris. Viral proteins were
immunoprecipitated with pooled patient sera, separated by SDS-PAGE, and
visualized by fluorography. For coimmunoprecipitation experiments, transfected
HeLa cells were lysed with GTN buffer containing 0.1% bovine serum albumin
(71). The cell lysates were centrifuged to remove cellular debris, Ubc9-Gag
complexes were immunoprecipitated with anti-Ubc9 antibodies that recognize
both endogenous Ubc9 and Myc-Ubc9, and the complexes were detected by
immunoblotting using anti-p24 sera.
Quantitation of gp160 processing efficiency. Autoradiograms were scanned
using a Fluor-S system. The accompanying Discovery Series Quantity One soft-
ware (Bio-Rad) was used to quantitate the intensities of the bands corresponding
to gp160 and gp120 from the scanned images. The molar equivalence of each
protein was calculated by dividing the band intensity by the number of methi-
onines for each protein (gp160 and gp120 contain 14 and 9 methionines, respec-
tively). To calculate the percentage of gp160 cleaved into gp120 in cells express-
ing Env only, the molar equivalence of gp120 was divided by the total molar
equivalence of Env (gp120 and gp160).
RESULTS
HIV-1 Gag interacts with hUbc9. While we have shown that
Ubc9 interacts with the full-length Gag protein of M-PMV,
others have not detected an interaction with the full-length
Gag proteins from other retroviruses. However, a Gag cleav-
age product, p6, was identified as a Ubc9 binding partner and
target for SUMOylation (21). Furthermore, recent work has
shown that HIV-1 GagGFP fusion protein is targeted to a
structure containing Ubc9 and SUMO-1 early in the assembly
pathway, suggesting that Ubc9 may play a role during the
assembly process (44). To test if an interaction between Ubc9
and HIV-1 Pr55 could be detected in vitro, Pr55 was translated
in vitro in the presence of [35S]methionine. GST-tagged Ubc9
was expressed in E. coli and purified using glutathione-agarose
beads. The GST-Ubc9-bound beads were mixed with in vitro-
translated Pr55. The bound proteins were eluted and examined
by SDS-PAGE and fluorography (Fig. 1a). While GST control
beads showed no detectable binding to Pr55, the GST-Ubc9
beads efficiently bound Pr55 under conditions previously used
to detect Ubc9–M-PMV Gag interactions. The 35-kDa band
that was pulled down with GST-Ubc9 is a peptide produced
during the in vitro transcription reaction from the use of an
internal ATG as the translation start site. This peptide could
contain the Gag/Ubc9 binding site. GST-Ubc9 pull-down assays
using a panel of Gag deletion mutants (Fig. 1b) showed that the
Ubc9 binding site on Pr55 is located within the carboxy-terminal
NC-p2-p6 region, since only clones pGPG1-39G1 and pGPG1-
15G1 retained the ability to be pulled down by GST-Ubc9 (Fig.
1c). These results were consistent with previous observations that
the p6 domain of Pr55 contains a Ubc9 binding site (21) and
demonstrated that the MA-CA-p1 regions of Pr55 do not contain
any additional major Ubc9 binding sites.
Coimmunoprecipitations confirmed that Ubc9 and Gag in-
teract in vivo (Fig. 2a). pNL4-3 or Pr55 was expressed in HeLa
cells alone or with Myc-tagged Ubc9. At 48 h posttransfection,
the cells were lysed using the same buffer used in the GST pull
downs and incubated with either polyclonal anti-Ubc9 antibod-
ies or preimmune rabbit sera. Immunoblots using anti-p24 sera
indicated that while the control preimmune sera did not pre-
cipitate Pr55, anti-Ubc9 antibodies coimmunoprecipitated
Pr55. The overexpression of Myc-tagged Ubc9 only increased
the amount of Pr55 pulled down by about 30%. The small
increase in the amount of Gag pulled down when Ubc9 was
overexpressed was not unexpected, as Ubc9 interactions with
target proteins were shown to be transient and weak (38).
To further substantiate Ubc9-Pr55 interactions in cells, im-
munofluorescence assays were utilized to examine Ubc9 and
Gag subcellular localization. 293T cells were transfected with
either Myc-Ubc9 expression plasmid alone (Fig. 2b to d) or
cotransfected with pNL4-3 and Myc-Ubc9 (Fig. 2e to j). The
cells were processed 48 h posttransfection and examined by
confocal microscopy. Myc-Ubc9 staining occurred in the nu-
cleus, throughout the cytoplasm, in areas near the plasma
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membrane (Fig. 2b to d, e, and h), and as distinct foci juxta-
posed to the nuclear membrane (Fig. 2b to d, e, and h). In cells
cotransfected with Myc-Ubc9 and pNL4-3 (Fig. 2e to j), HIV-1
Gag stained the cytoplasm and plasma membrane and at pe-
rinuclear foci (Fig. 2f). HIV-1 Gag and Ubc9 colocalized in
HIV-1-expressing cells (Fig. 2g) in a similar pattern that was
observed with M-PMV Gag and Ubc9 in infected cells (71) and
is similar to what was observed recently for HIV-1 GagGFP
fusion protein (44). Gag was also observed to colocalize with
Ubc9 in the cytoplasm near the plasma membrane and at
perinuclear foci (Fig. 2g). In an effort to identify the Gag-Ubc9
colocalization site and to determine whether Ubc9 and Env
also colocalize, we stained for both Env and Ubc9. Env and
Ubc9 did not seem to colocalize (Fig. 2h to j), and certainly not
at the same punctate perinuclear site observed between Gag
and Ubc9. Furthermore, these results suggest that the Ubc9/
Gag foci observed in this study are not in the ER, Golgi
apparatus, or post-Golgi vesicles, all cellular organelles that
Env is known to occupy. These results are similar to those
reported by Martinez et al., where they described a similar
subcellular site containing Gag, Ubc9, and SUMO-1 (44).
Ubc9 is important for the production of infectious HIV-1
particles. Having determined that Ubc9 interacts with the full-
length HIV-1 Gag protein, we sought to further elucidate the
role of Ubc9 in the production of replication-competent HIV-1
particles by ascertaining whether infectious virions could be
produced in the absence of Ubc9 expression. To achieve this,
293T cells were transfected twice with either a nonsilencing
Ctr. RNA or a Ubc9-specific silencing RNA (Ubc9 RNAi) at
24-h intervals, followed by transfection with wt HIV-1 proviral
DNA (pNL4-3) after an additional 24 h. The effects of Ubc9
RNAi transfection on Ubc9 expression, cell viability, virus pro-
duction, and viral infectivity were assayed 72 h after the initial
RNA transfection. As shown in Fig. 3a, Ubc9 expression was
reduced to almost undetectable levels in cells transfected with
Ubc9 RNAi compared to cells transfected with the Ctr. RNA.
The levels of the controls, p53 and actin, remained constant in
all samples, demonstrating the specificity of Ubc9 silencing.
Because Ubc9 is required to sustain cellular replication (24),
we examined cell viabilities at 72 h posttransfection, when
media containing virions were collected. Flow cytometry quan-
tifying propidium iodide incorporation, Annexin V staining,
and trypan blue exclusion (data not shown) assays demon-
strated that greater than 97% of control RNA- and Ubc9
RNAi-transfected cells were viable when the virions were har-
vested (Fig. 3b).
To examine whether Ubc9 is important during virus assem-
bly and release, cell-free virions released into culture superna-
tants from transfected cells were pelleted, lysed, and analyzed
by Western blotting. We found that Ubc9 expression is not
required for virus assembly, budding, or Pr55 processing, since
equivalent amounts of p24 were released from cells as pellet-
able virus particles in the presence or absence of Ubc9 expres-
sion (Fig. 3c). These virions also contained equivalent amounts
of reverse transcriptase (data not shown). The effect of Ubc9
depletion on virion infectivity was analyzed by using equivalent
numbers of virions (normalized to p24 content) released from
these cells in an infectivity assay using TZM-bl reporter cells to
quantify the infectious events relative to virions produced in
the presence of Ubc9. Virions released from cells that did not
express detectable levels of Ubc9 were on average 8- to 10-fold
less infectious than those virions released from cells expressing
normal levels of Ubc9 (Fig. 3d). The average viral titers for
cells transfected with no RNA, Ctr. RNA, and Ubc9 RNAi
were 3,750, 4,083, and 367, respectively. These results are the
first to demonstrate that while Ubc9 has no effect on Gag
synthesis, processing, or assembly into virions, its expression in
the producer cells is important for the generation of infectious
HIV-1 virions.
Ubc9 is important for the correct production and packaging
of viral components. We initially anticipated that Ubc9 must
be packaged into HIV-1 virions to achieve full infectivity. How-
ever, this scenario appears unlikely, since we and others (9)
were unable to detect Ubc9 or SUMO-1 in HIV-1 particles
released from cells even when myc-Ubc9 was overexpressed in
the producer cells (data not shown). Our results (Fig. 3c)
demonstrated that the interaction between Gag and Ubc9 is
not required for Gag release and processing but is important
for infectivity (Fig. 3d). Therefore, Ubc9 must influence Gag-
FIG. 1. HIV-1 Gag proteins interact with Ubc9 in vitro. (a) GST-
Ubc9 pull-down assay. [35S]methionine-labeled in vitro-translated Pr55
was incubated in GTN buffer with GST-bound glutathione beads or
GST-Ubc9-bound beads. As a loading control, 1/10 of the amount of
Pr55 added to the GST pull-down reaction mixtures was loaded di-
rectly. Bound proteins were eluted with PSB and separated by SDS-
PAGE. The radiolabeled proteins were visualized by phosphorimag-
ing. (b) Mapping the Ubc9 binding domain within HIV-1 Gag. (c)
GST-Ubc9 pull-down assays using wt Gag and the Gag deletion mu-
tants were done as described above.
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mediated biosynthesis, the packaging of other viral compo-
nents, or the inclusion of cell-derived viral inhibitors. The
deficiency in assembly of released virions was identified by
comparing the composition of replication-defective virions
harvested from Ubc9 knockdown cells to that of fully infectious
HIV-1 from normal and control RNA-transfected cells.
As shown, Ubc9 expression was not required for packaging
of the vRNA (Fig. 4a); the HIV-1 accessory proteins Vpr, Vpu,
and Vif; or the cellular protein cyclophilin A (Fig. 4b). In
contrast, virions produced in the absence of Ubc9 expression
contained significantly smaller amounts of Env glycoproteins
(gp120, and gp41) than virions produced from cells transfected
with pNL4-3 alone or with pNL4-3 and control RNA (Fig. 4c).
Env production was assayed in these producer cells, and it was
FIG. 2. HIV-1 Gag proteins interact with Ubc9 in vivo. (a) Coimmunoprecipitation of endogenous Ubc9 and HIV-1 Gag. HeLa cells were
either mock transfected (Untrans.) (lanes 1 and 5); cotransfected with pCMVgagpol-RRE-R and pCMVrev (lane 2 and lane 4); cotransfected with
pCMVgagpol-RRE-R, pCMVrev, and pCMV Myc-Ubc9 (lane 3); or transfected with pNL4-3 (lane 6). The cells were lysed with GTN buffer and
immunoprecipitated with anti-Ubc9 (lanes 1, 2, 3, 5, and 6) or preimmune sera (lane 4), and analyzed by immunoblotting using anti-p24 antibodies.
(b to j) Gag and Ubc9 colocalize at distinct perinuclear puncta and areas near the plasma membrane. 293T cells were transfected with Myc-Ubc9
(b to d) or cotransfected with pNL4-3 and Myc-Ubc9 expression plasmid (e to j). The cells were fixed and processed for immunofluorescence with
anti-Ubc9 PAb (b to d), anti-p24 MAb and anti-Ubc9 PAb (e to g), or anti-Ubc9 PAb and 10E9 anti-Env MAb (h to j). Cy5-conjugated donkey
anti-mouse and Cy2-conjugated donkey anti-rabbit antibodies were used as secondary antibodies. Colocalization was examined by confocal
microscopy using 0.3-m optical sections. Representative medial sections are shown. The yellow arrowheads indicate the perinuclear sites where
Ubc9 and Gag should colocalize. The white arrowheads indicate areas where Ubc9 and Gag should colocalize near the plasma membrane. Scale
bars, 10 m.
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found that cells transfected with pNL4-3 and Ubc9 RNAi con-
tained similar amounts of the Env precursor protein gp160 but
exhibited a decrease in gp120 and gp41 levels compared to
those that were transfected with pNL4-3 alone or with pNL4-3
and Ctr. RNA (Fig. 4d).
The changes observed in gp120 expression and packaging
were unexpected and suggested that the decrease in virion
infection may be due to the inability of the virions to attach to
and enter a susceptible cell; however, the SUMOylation path-
way has also been implicated during early infectious events of
HIV-1 (21) and MLV (76). Gurer et al. had previously shown
that overexpression of SUMO-1 in producer cells leads to a
decrease in HIV-1 virion infectivity, which was attributed to a
defect during an early step of reverse transcription of the viral
genome. Similarly, Yueh et al. reported that point mutations of
lysines (K202 and K220) that block the SUMOylation of the
capsid protein of MLV also resulted in a defect at an early
infectious event, albeit at a post-reverse-transcription step.
To examine the possibility that the decrease in virion infec-
tivity could be attributed to defects that occurred during
postentry events, we assayed the ability of vesicular stomatitis
virus G protein-pseudotyped HIV-1 cores to complete early
infection events and nascent viral-gene expression. These ex-
periments allowed us to examine early events independently of
any potential defects in entry caused by the decreased Env
packaging in the absence of Ubc9 expression. Virion infectivity
was carried out as before using TZM-bl indicator cells. As
shown in Fig. 4e, the decreased expression of Ubc9 by RNAi
had no affect on the infectivity of the pseudotyped HIV-1
cores. These data indicated that the defect observed with viri-
ons produced in the absence of Ubc9 expression was not due to
a defect during early postentry events but was likely the result
of the virions’ inability to enter a susceptible cell as a result of
the decreased amount of Env packaged.
Ubc9 contributes to viral glycoprotein stability in the pres-
ence of Gag expression. Immunoblot data that examined viral
proteins at steady-state levels showed a significant decrease in
the amount of gp120/gp41 in the transfected cells and in the
amount of Env packaged into the virions. The decrease in
gp120 in the producer cells suggested that this could be due to
a defect in gp160 maturation, a decrease in the stability of
gp120, or a lower number of mature virions being endocytosed
in the absence of Ubc9 expression. A defect in gp160 matura-
tion was less likely, as immunoblot data (Fig. 4d) did not show
the increase in gp160 expression levels at steady state, which
was expected if gp160 was not undergoing cleavage during
maturation. Therefore, pulse-chase experiments were carried
out to further examine these possibilities and to access Env
FIG. 3. Ubc9 is important for the production of infectious HIV-1
virions. (a) Ubc9 expression can be suppressed by RNA silencing. 293T
cells were transfected with either Ctr. RNA or Ubc9 siRNA. A second
transfection with the RNAs was performed 24 h later. The cells were
lysed in PSB and separated by SDS-PAGE, and protein expression
levels were analyzed by immunoblotting using antibodies against Ubc9,
actin, and p53 72 h after the initial siRNA transfection. (b) Suppres-
sion of Ubc9 does not affect cell viability. The viability of Ctr. RNA-
and/or Ubc9 RNAi-transfected 293T cells was analyzed using the BD
ApoAlert Annexin V and Apo 2.7-PE kit following the manufacturer’s
suggested protocol. The percentages of cells undergoing apoptosis
were measured by flow cytometry. (c) Ubc9 is not required for bud-
ding. 293T cells were either left untreated or transfected twice with
Ubc9 siRNA or Ctr. RNA. Wt HIV-1 proviral DNA (pNL4-3) was
transfected 24 h following the second siRNA transfection. Twenty-four
hours later (72 h after the initial siRNA transfection), the culture
medium was collected and clarified. Virions in the culture medium
were pelleted through a 20% sucrose cushion and lysed with PSB.
Equal volumes of the lysates were separated by SDS-PAGE, and p24
levels were measured by immunoblotting using anti-p24 antibodies. (d)
Ubc9 in virus-producing cell is required for HIV-1 infectivity. An
amount of virus normalized to pelletable p24 present in the medium
from transfected 293T cells was used to infect TZM-bl indicator cells
for 36 h. The numbers of infectious events were analyzed by counting
the cells that were positive for X-Gal (5-bromo-4-chloro-3-indolyl--
D-galactopyranoside) staining. The error bars indicate standard devi-
ations.
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stability in the absence of Ubc9 expression. Equivalent
amounts of Env and Gag proteins were synthesized in all
samples (Fig. 5a). However, a 90% reduction in Ubc9 expres-
sion resulted in an approximately twofold decrease in the
amount of cell-associated gp120 (Fig. 5a and c). This reduction
in cell-associated gp120 was not due to a defect in gp160
processing or an increased release of gp120 into the media
(Fig. 5a and b). When pulse-labeled Gag proteins were chased,
FIG. 4. Biochemical composition of viral particles. The relative levels of vRNAs and proteins packaged into equivalent numbers of defective and
infectious virions (normalized to the p24 content) were analyzed. (a) VRNA packaging. RNA from pelleted virions was extracted, reverse transcribed
using oligo(dT) 12-18, and quantified by real-time PCR using vRNA-specific primers. Real-time PCR data from three independent experiments is shown
as the amount of vRNA packaged into virions relative to that of vRNA packaged into virions produced from cells transfected with pNL4-3 only. The error
bars indicate standard deviations. (b) Packaging of cellular and HIV-1 regulatory proteins. The levels of cellular (cyclophilin A [Cyp A]) and viral (Vif,
Vpr, and Vpu) regulatory proteins packaged into virions were analyzed by immunoblotting. The bands were quantified using Discovery Series Quantity
One software. (c) Glycoprotein packaging into virions. Envelope packaging into virions was analyzed by immunoblotting using polyclonal anti-HIV-1 and
monoclonal anti-gp41 antibodies. (d) Glycoprotein production in cell lysates. Envelope production inside transfected cells was analyzed by immuno-
blotting using polyclonal anti-HIV-1 and monoclonal anti-gp41 antibodies. (e) Decreases in virion infectivity are not due to defects in early postentry events.
Cells were transfected with RNAs as in previous experiments, followed by DNA transfections with pNL4-3-E-EGFP and pHyg-VSV-G or pNL4-3Env alone.
Media containing pseudotyped virions were harvested and clarified 24 h after DNA transfections. Virion infectivity assays were carried out as before using
TZM-bl target cells. Ubc9 expression in cell lysates. No RNA (lanes 1 to 4), control RNA (lanes 5 to 7), Ubc9 RNAi (lanes 8 to 10).
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the levels of cell-associated Pr55 decreased, as virus-associated
p24 increased at the same rates regardless of the Ubc9 expres-
sion levels. The amount of cell-associated p25/p24 did not
change relative to the control cells, indicating that the decrease
in cell-associated gp120 was not due to decreased endocytosis
of mature virions.
The amount of gp120 packaged into particles released from
Ubc9 RNAi-treated cells was also approximately twofold less
than that packaged into the particles released from control
cells. This is consistent with what was observed in the amounts
of cell-associated gp120. The small amount of gp120 that was
detected in Ubc9 RNAi-transfected cells and released into the
media was probably from cells that were not transfected with
the Ubc9 RNAi. These data suggest that Ubc9 plays an im-
portant role in determining gp120 levels in the virus-producing
cells, either directly or indirectly, resulting in decreased pack-
aging of gp120 into the released virions.
Ubc9 has been reported to interact with a variety of cellular
proteins affecting subcellular location, function, and stability
(45). Some of these proteins have biosynthetic pathways sim-
ilar to those of HIV-1 Env and are found in organelles known
to be utilized by Env in the late virion assembly pathway (11,
62, 74). Because Ubc9 has been shown to act directly upon
cellular glycoproteins utilizing the secretory pathway, pulse-
chase experiments that assayed Env stability were done in the
absence of Gag expression to rule out the possibility that Ubc9
was directly acting upon Env. This was carried out by using
pNL4-3 that was modified to express Env glycoproteins in the
absence of Pr55 by deleting the gag and pol genes. 293T cells
were transfected with this construct (long terminal repeat
[LTR] EnvNL4-3) either alone or with the Ctr. RNA or Ubc9
siRNA. Env-processing kinetics and stability were examined by
pulse-chase experiments at 24 h posttransfection. Surprisingly,
in the absence of Gag, pretreatment of cells with Ubc9 RNAi
had no effect on the amount of gp160 that was synthesized and
processed or on the kinetics and efficiency of processing gp160
into gp120 and gp41 (Fig. 6). We concluded from these exper-
iments that Ubc9, in the absence of Gag, does not play a
significant role either in gp160 cleavage, in trafficking through
the secretory pathway to the TGN, or in gp120 stability. To-
gether, these results demonstrate that Ubc9 functions during
the virus assembly process, which is required for full infectivity,
and suggest that Ubc9 is involved in the processing and pack-
aging of mature Env glycoproteins.
Ubc9 functions independently of its E2 SUMO conjugase
activity. Ubc9 is the only E2 SUMO-conjugating enzyme iden-
tified (19), and many of the Ubc9-interacting partners are
substrates for SUMOylation. However, there are an increasing
number of reports that demonstrate that Ubc9 also functions
in a SUMO conjugase-independent manner (3, 8, 32, 36, 53,
59, 69). To determine whether Ubc9 SUMO conjugase activity
is involved or required for its interaction with Gag and if it
affects viral infectivity, we tested the effect of the overexpres-
sion of a trans-dominant-negative mutant, C93A, that has no
E2 SUMO conjugase activity (68). 293T cells were cotrans-
fected with equal amounts of EGFP–SUMO-1 and pCMV-
Tag3A (empty vector) or EGFP–SUMO-1 and Myc-C93A or
with pCMV-Tag3A alone to confirm that Myc-C93A acts as a
FIG. 5. Gag and Env processing in the absence of Ubc9. (a and b) Viral-protein assembly kinetics. 293T cells were transfected with NL4-3,
NL4-3 plus Ctr. RNA, or NL4-3 plus Ubc9 RNAi or left untransfected (U). The cells were pulsed (P) with [35S]methionine for 45 min and then
chased for 2 and 4 h. HIV-1 proteins in the cell lysates (a) and the culture supernatants (b) were immunoprecipitated with pooled AIDS patient
sera, separated by SDS-PAGE, and detected by fluorography. The viral-protein bands from multiple pulse-chase experiments were quantified and
analyzed using Discovery Series Quantity One software. (c) Ratio of cellular gp120/Pr55. (d) Ratio of gp120/p24 released into the media. The error
bars indicate standard deviations.
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trans-dominant negative. Endogenous SUMO-1 is the limiting
factor for SUMOylation (14); thus, overexpression of exoge-
nous EGFP–SUMO-1 proteins greatly increases the amount of
SUMOylated proteins detected by immunoblotting. A fourfold
overexpression of Myc-C93A over endogenous Ubc9 led to an
approximately 70% decrease in the global amount of EGFP-
SUMOylated proteins. Quantitation of the 80-kDa band dem-
onstrated a 90% decrease compared to the control (Fig. 7a).
This result suggests that overexpression of Myc-C93A can in-
hibit SUMOylation effectively.
To examine if the SUMOylation activity of Ubc9 is impor-
tant for HIV-1 infectivity, 293T cells were cotransfected with
pNL4-3 and either pCMV-Tag3A (Fig. 7b, set 1), Myc-Ubc9
(Fig. 7b, set 2), or Myc-C93A (Fig. 7b, set 3). As expected,
immunoblot analysis of whole-cell lysates and virions pelleted
from the media of transfected cells showed that the overex-
pression of either Ubc9 or C93A had no effect on virion bud-
ding, maturation, or release (Fig. 7b). We then further exam-
ined whether the virions produced in the presence of the C93A
mutant displayed decreased infectivity. As in previous experi-
ments, the released virions were normalized for p24 content,
and equal numbers of virions were used to infect TZM-bl
indicator cells. In contrast to the loss of virion infectivity ob-
served in the absence of Ubc9, overexpression of C93A and
inhibition of SUMOylation in the producer cells had little
effect on virion infectivity compared to control samples (Fig.
7c). In addition, Gag trafficked normally to perinuclear sites
and colocalized with C93A Ubc9 (Fig. 7d). Collectively, these
results suggest that Ubc9 may function independently of its E2
SUMO-conjugating activity during the late stages of the HIV-1
life cycle.
DISCUSSION
In this study, we have shown that Ubc9 interacts with the
full-length HIV-1 Gag protein and have demonstrated for the
first time that Ubc9 plays a role during the late stages of virus
replication and that its expression in HIV-1-producing cells is
important for conferring full infectivity on the nascent virus
stock. Our results indicate that Ubc9 influences the stability
and incorporation of mature Env into budding particles and
that it may function during the HIV-1 assembly process in a
SUMO-independent manner. These conclusions are supported
by the following: (i) Ubc9-GST fusion proteins can interact
with in vitro-translated Gag through its NC-p6 domain; (ii)
Gag-Ubc9 complexes can be coimmunoprecipitated from cell
lysates; (iii) Gag, Ubc9, and trans-dominant-negative C93A
colocalize to discrete locations in the cytoplasm; (iv) overex-
pression of Ubc9 or C93A does not affect virion infection; (v)
Ubc9 silencing leads to impaired virion infectivity; (vi) Ubc9
silencing has no effect on Gag assembly, budding, and process-
ing or on Gag-mediated packing of the vRNAs, Vif, Vpr, Vpu,
or the cellular protein cyclophilin A; (vii) Ubc9 is important for
proper Env stability and incorporation of mature Env glyco-
proteins into virion particles when Env is expressed in the
context of wt HIV-1 replication; and (viii) Ubc9 and Env do
not appear to colocalize at the distinct perinuclear foci that
contain Ubc9 and Gag.
While most studies that have characterized Env processing
and stability were carried out in Env-only expression systems,
our data suggested that in the context of wt HIV-1, Gag and
Ubc9 are important for Env stability and incorporation into
nascent virions. It was unexpected that the knockdown of a
Gag-interacting partner would cause a change in Env stability
and packaging, but it was even more so to find that this phe-
notype was directly tied to the presence or absence of Gag
expression. While many have speculated that Env trimers in-
teract with Gag at budding sites, biochemical and genetic ev-
idence suggests that the initial Gag-Env interactions, whether
direct or indirect, occur prior to their arrival at the assembly
sites (13, 41–43, 52).
The mechanism by which Gag influences gp120 stability in
the absence of Ubc9 has not been elucidated, but our data
suggest that the Gag/Ubc9 complex could interact/affect Env
after it has passed through the trans-Golgi, possibly in secre-
tory vesicles, the plasma membrane, or recycling endosomes.
Our data suggest that Ubc9 is not involved directly with Env
processing, as gp160 processing and gp120 stability are normal
in the absence of Gag and Ubc9, and Env and Ubc9 do not
strongly colocalize in the same subcellular compartments. Al-
though the majority of Ubc9-Gag colocalization is at perinu-
clear foci, which may be the Ubc9/SUMO-1-positive cellular
FIG. 6. Env processing in the absence of Gag and Ubc9 expression.
(a) Ubc9 does not directly affect Env processing. 293T cells were trans-
fected with LTR-Env, LTR-Env plus Ctr. RNA, or LTR-Env plus Ubc9
RNAi or left untransfected (U). The cells were pulsed (P) with [35S]me-
thionine for 45 min and then chased for 2 and 4 h. HIV-1 proteins were
immunoprecipitated from cell lysates with AIDS patient sera. (b) Immu-
noprecipitated gp160 and gp120 bands were quantitated using Discovery
Series Quantity One software, and the percentages of gp160 processed
were calculated at 2 and 4 h. The error bars indicate standard deviations.
(c) Summary of proteins involved in Env stability.
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structures through which GPCs transiently traffic during an
early stage of assembly (44), colocalization was observed in
areas adjacent to the plasma membrane with both Ubc9 and
C93A, as well. It is possible that this area is a functional
subcellular site of interaction between Ubc9 and Gag. The
close proximity of this colocalization site to the plasma mem-
brane and the physical distance from the distinct perinuclear
foci containing Gag and Ubc9 suggest that Ubc9 may also
function at a later stage of assembly, a stage in which Gag has
already trafficked through assembly intermediates and has
been targeted to and is in close proximity to the plasma mem-
brane, possibly at virus assembly sites.
The trafficking of Gag to the sites of Ubc9 colocalization
is most likely very transient, as overexpression of Myc-Ubc9
greatly increases the amount of Gag localization to perinuclear
sites containing Ubc9 but does not lead to a change in the amount
of Gag released into the medium as virions. If Gag trafficking to
sites of Ubc9 colocalization were not transient or Gag trafficking
to assembly sites slowed, we would have expected a difference
between the numbers of virions released from cells when Ubc9 or
C93A was overexpressed. However, this phenotype was not ob-
served, suggesting very transient Gag trafficking through the sites
of Ubc9 colocalization. The full extent of how Ubc9 functions
during the HIV-1 life cycle is still not well understood, and it may
be involved with various steps during assembly.
Ubc9 is an E2 SUMO conjugase that is part of the cytoplas-
mic portion of the nuclear pore complex (77). It appears to
localize to distinct, yet undefined, perinuclear regions and the
secretory pathway and is also free in the cytoplasm (44, 62, 71,
74). Ubc9, through its SUMOylation activity, is involved in the
targeting of transcription factors, cellular receptors, and viral
proteins (reviewed in references 19, 26, and 45). However,
there are a number of reports in the literature demonstrating
that Ubc9 functions in a SUMO-independent manner. Andro-
gen receptor (8), MEKK1, type I tumor necrosis factor alpha
receptor (59), GLUT4 (40), RNA helicase A (3), glucocorti-
coid receptors (32), Vsx-1 (36), SOX4 (53), and human her-
pesvirus 6 IE2 (69) require Ubc9 binding for their functions
and correct intracellular targeting, but they are not targets for
SUMO-1 modification.
Our experiments with the dominant-negative C93A support
a model in which Ubc9 functions as an essential binding part-
FIG. 7. Ubc9 may function independently of its E2 SUMO-conjugating activity during HIV-1 assembly. (a) Myc-C93A is a trans-dominant-negative
active-site mutant and suppressed SUMOylation of cellular proteins. 293T cells were cotransfected with pEGFP-SUMO-1 and either pCMV-Tag3A (lane
2) or Myc-C93A (lane 3), with pCMV-Tag3A alone (lane 4), or left untransfected (lane 1). The cells were washed with PBS, lysed in SUMO lysis buffer,
and boiled for 10 min. The lysates were assayed by immunoblotting using antibodies against SUMO-1 and Ubc9. (b) Overexpression of Myc-Ubc9 or
Myc-C93A does not affect virion budding. 293T cells were cotransfected with pNL4-3 and either PCMV-Tag3A (sample set 1), Myc-Ubc9 (sample set
2), or Myc-C93A (sample set 3) or left untreated (Un). The media were harvested, and virions were pelleted through a 20% sucrose cushion. Virion
budding and release were assayed by immunoblotting using antibodies against p24. The transfected cells were lysed directly in PSB, and protein expression
was analyzed by immunoblotting using antibodies against Ubc9 and actin. (c) Overexpression of Myc-Ubc9 or Myc-C93A does not affect HIV-1
infectivity. Medium from transfected cells was harvested, and equal amounts of virus were used to infect TZM-bl indicator cells, as in previous
experiments. The error bars indicate standard deviations. (d) HIV-1 Gag and Myc-C93A do not affect Gag trafficking or colocalization with Ubc9 at
perinuclear sites. Transfected 293T cells were fixed and processed for immunofluorescence analysis by confocal microscopy, using anti-Ubc9 PAb and
anti-p24 MAb. Cy5-conjugated donkey anti-mouse and Cy2-conjugated donkey anti-rabbit antibodies were used as secondary antibodies. Colocalization
was analyzed using 0.3-m optical sections. Representative medial sections are shown. The yellow and white arrowheads indicate areas of Ubc9 and Gag
colocalization at perinuclear puncta and near the plasma membrane, respectively. Scale bars, 10 m.
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ner of Gag in the late HIV-1 life cycle but may do so indepen-
dently of its SUMOylation conjugation function. If SUMOy-
lation was important during the late stages of the HIV-1 life
cycle, we would have expected to see a difference in virion
infectivity with the trans-dominant C93A mutant compared to
virions produced in control cells, yet little difference was ob-
served. This model is supported by data reported by Gurer et
al., in which the mutant HIV-1K27R displayed no defects in
virion assembly, even though it contained a mutated version of
an in vivo SUMOylation site within p6. We have attempted to
detect SUMOylated Gag or other viral proteins in both cell
lysates and released virions at steady-state levels and when
Ubc9 and SUMO-1 have been overexpressed but have been
unsuccessful. It is interesting that p6 (K27R) showed dimin-
ished Ubc9 binding in a yeast two-hybrid system (21), but the
mutation did not abolish its interaction with Ubc9 completely.
Because of this, we carried out GST-Ubc9 pull-down experi-
ments with K27R in the context of Pr55 and found that p6
(K27R) can still interact with Ubc9 in vitro (data not shown).
This result suggests that there is more than one Ubc9 binding
site within Gag or that mutation of lysine 27 in p6 is not enough
to completely abolish Ubc9 binding.
In this study, we mainly focused on the effects of Ubc9 on
the late events of the viral life cycle in producer cells. Even
though Ubc9 is not packaged into virions at steady-state levels
or when Ubc9 is overexpressed (data not shown), it has been
reported that SUMO-1 plays a role during the early infectious
events of HIV-1 (21, 76) and that it may regulate various steps
within the retrovirus life cycle. To further understand the
mechanisms by which Ubc9 functions in the HIV-1 life cycle,
studies following Gag and Env trafficking in the absence of
Ubc9 are currently under way. We are also investigating
whether Ubc9 plays a direct role during the early infectious
events of HIV-1 in target cells after entry. Our data show that
Ubc9 plays an important role during HIV-1 replication, and we
have identified another protein/pathway that could potentially
be developed into novel antiretrovirals.
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